BioNexus Gene Lab Corp.
BioNexus Gene Lab Corp. (BGLC) Revenue
Annual & quarterly revenue history · segment & region breakdown
BGLC · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsBioNexus Gene Lab Corp. trailing twelve-month (TTM) revenue is $0.01B, a decrease of 21.93% year-over-year from $0.01B in FY2025.
Revenue trend
2025 – 2016 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.01B | -$0.00B | -21.93% |
| 2024-12-31 | $0.01B | -$0.00B | -2.66% |
| 2023-12-31 | $0.01B | -$0.00B | -10.60% |
| 2022-12-31 | $0.01B | -$0.00B | -18.21% |
| 2021-12-31 | $0.01B | +$0.00B | +17.31% |
| 2020-12-31 | $0.01B | +$0.01B | +8872.03% |
| 2019-12-31 | $0.00B | -$0.00B | -40.21% |
| 2018-12-31 | $0.00B | +$0.00B | +97.18% |
| 2017-12-31 | $0.00B | +$0.00B | — |
| 2016-12-31 | $0.00B | — | — |
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income BioNexus Gene Lab Corp. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
BioNexus Gene Lab Corp. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from BioNexus Gene Lab Corp.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
BGLC revenue · 4 questionsBGLC's trailing twelve-month (TTM) revenue is $0.01B. That is a decrease of 21.93% year-over-year from $0.01B in FY2025.
▸ Source: FMP · BioNexus Gene Lab Corp. SEC filings · GAAP · BioNexus Gene Lab Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026